MDT Medtronic plc
Electromedical & Electrotherapeutic Apparatus · NYSE · SEC CIK 1613103 · Fiscal year ends 04/24
Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.8%
TTM net income YoY12.3%
TTM EPS YoY12.2%
Revenue 3-yr CAGR6.0%
Net income 3-yr CAGR13.1%
Margins
Gross margin65.0%
Operating margin18.1%
Net margin13.9%
FCF margin16.3%
EBITDA margin23.5%
Returns
ROE10.7%
ROA5.7%
ROIC (approx.)7.1%
Asset turnover0.41x
Leverage & solvency
Liabilities / assets45.5%
Debt / equity0.56x
Current ratio2.07x
Interest coverage9.37x
Cash quality & payout
Operating cash flow / net income1.54x
Accruals ratio-3.0%
Payout ratio69.8%
Capex / revenue5.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-04-24 | FY20252025-04-25 |
|---|---|---|
| Income statement | ||
| Revenue | $36.36B | $33.54B |
| Cost of revenue | $12.72B | $11.63B |
| Gross profit | $23.64B | $21.91B |
| R&D expense | $2.87B | $2.73B |
| SG&A expense | $11.78B | $10.85B |
| Operating income | $6.47B | $5.96B |
| Interest expense | $715.00M | $729.00M |
| Pretax income | $6.14B | $5.63B |
| Income tax | $1.30B | $936.00M |
| Net income | $4.80B | $4.66B |
| EBITDA | $9.43B | $8.82B |
| EPS (basic) | 3.75 | 3.63 |
| EPS (diluted) | 3.73 | 3.61 |
| Dividends declared per share | 2.84 | 2.80 |
| Weighted avg. shares (diluted) | 1.29B | 1.29B |
| Banking | ||
| Net interest income | $383.00M | $511.00M |
| Balance sheet | ||
| Cash & equivalents | $1.95B | $2.22B |
| Short-term investments | $7.27B | $6.75B |
| Receivables | $6.64B | $6.51B |
| Inventory | $5.95B | $5.48B |
| Current assets | $24.79B | $23.81B |
| PP&E, net | $7.42B | $6.84B |
| Goodwill | $42.59B | $41.74B |
| Intangibles | $10.15B | $11.67B |
| Total assets | $93.03B | $91.68B |
| Current liabilities | $11.66B | $12.88B |
| Short-term debt | $1.79B | $2.87B |
| Long-term debt | $26.17B | $25.64B |
| Total debt | $27.96B | $28.52B |
| Total liabilities | $42.96B | $43.42B |
| Shareholders' equity | $49.46B | $48.02B |
| Net debt | $26.01B | $26.30B |
| Shares outstanding | 1.28B | 1.28B |
| Cash flow statement | ||
| Operating cash flow | $7.33B | $7.04B |
| Capital expenditure | $1.90B | $1.86B |
| Free cash flow | $5.43B | $5.18B |
| Investing cash flow | -$2.93B | -$1.94B |
| Financing cash flow | -$4.75B | -$4.36B |
| Depreciation & amortization | $2.96B | $2.86B |
| Stock-based compensation | $457.00M | $429.00M |
| Dividends paid | $3.64B | $3.59B |
| Share buybacks | $1.03B | $3.23B |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.